 high- versu standard-dos megestrol acet women advanc breast cancer phase iii trial piedmont oncolog associ seventy-two patient advanc breast cancer oral standard-dos megestrol acet MA mg/d high-dos MA mg/d patient prior trial tamoxifen therapi metastat diseas adjuv treatment pretreat characterist similar arm high-dos MA superior complet partial respons rate time treatment failur median month surviv median month standard-dos therapi differ signific adjust covari patient high-dos MA failur standard-dos MA treatment none weight gain distress side effect standard-dos high-dos patient lb major cardiovascular event patient high-dos treatment patient standard dose other toxic modest high-dos MA signific improv secondari endocrin therapi advanc breast cancer patient initi endocrin treatment use regular basi result clinic trial